Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT)
Michael Hodsdon, Adam Abel, Antonio Chambers, Ming Lu, Amanda Morris, Michael Pontecorvo, Heinz Reiske, Emily C Collins, Mark Mintun, Andrew E Schade, Rose C Beck · 2025
Read Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT) by Michael Hodsdon, Adam Abel, Antonio Chambers, Ming Lu, Amanda Morris, Michael Pontecorvo, Heinz Reiske, Emily C Collins, Mark Mintun, Andrew E Schade, Rose C Beck (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713898.txt.
Description
Michael Hodsdon and co-authors test a blood test for Alzheimer's disease in a 2025 study. Blood tests could make diagnosis far easier than spinal taps or brain scans. The test reads a changed form of tau protein in blood plasma. The team checks how well the test flags the amyloid buildup that brain scans show.
Plasma came from more than 2,000 people screened for a large drug trial. Scores from the blood test matched scan results with strong accuracy. Two cut-off points sorted people into likely positive, likely negative, and unsure groups. Fewer than one in five people landed in the unsure band. A simple blood draw, the study suggests, can sort most patients without a scan.
Catalog record
| CREATOR | Michael Hodsdon, Adam Abel, Antonio Chambers, Ming Lu, Amanda Morris, Michael Pontecorvo, Heinz Reiske, Emily C Collins, Mark Mintun, Andrew E Schade, Rose C Beck |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |